Over the last few years results from clinical trials and adaptive phase 1 studies such as those offered by https://www.richmondpharmacology.com/specialist-services/adaptive-phase-i-studies have produced some amazing results with regards to conditions that people live with each day. These studies often produce results that enable new drugs to be used to combat certain conditions. Some of the research and papers that have been presented in the past offer real hope to kidney disease sufferers and potential treatments for clinicians.
The Liraglutide Effect and Action in Diabetes trial focussed on 9,340 types 2 diabetes sufferers who were randomly given either liraglutide (a glucagon-like peptide-1 analogue) or a placebo. The results were correlated over the next four years and revealed a 21 percent fall in the risk of death from kidney disease in the patients using liraglutide. The conclusion is that liraglutide impacted on the progression of diabetic nephropathy in patients.
Liraglutide and renal outcomes in type 2 diabetes
The trial looked at kidney function after transplantation in 406 pairs of living donors and recipients, using remote ischemic preconditioning (RIPC). The results saw a 13 percent improvement in kidney function, which had a sustained, long-term effect for five years after transplant. The trial’s authors are recommending that RIPC becomes a routine part of care in such situations. By reducing blood flow in donors and patients before surgery, internal organs become resistant to low blood flow post-transplant.
Successful treatment of active lupus nephritis with voclosporin
The effect of voclosporin on remission rates for lupus nephritis is very promising, with voclosporin performing much better than a placebo in both high and low doses. The side effects showed consistency with raised immunosuppression. The results are likely to lead to more studies and trials of the effects of voclosporin on active lupus nephritis.
Rabbit antithymocyte globulin instead of basiliximab
The study looked at 615 transplant patients who were randomly assigned a basiliximab induction with mycophenolate mofetil, low dose tacrolimus, and steroid maintenance therapy (arm A); rapid corticosteroid withdrawal on day eight (arm B); or rapid corticosteroid withdrawal on day eight after rabbit anti-thymocyte globulin (ATG) rather than basiliximab (arm C). The levels of rejection across all groups were similar and the rabbit ATG did not prove a better solution to basiliximab. The researchers did conclude, however, that there are still some advantages to rapid steroid withdrawal in post-transplantation diabetes mellitus incidence.